ANDOVER, Mass., June 7, 2011 /PRNewswire/ -- Smith & Nephew, Inc., Endoscopy Division, a subsidiary of Smith & Nephew plc (NYSE: SNN) (London Stock Exchange: SN) announced today that the next phase of its patent infringement case against Arthrex Inc. (Naples, Fla.) -- claiming that use of Arthrex’s Bio-SutureTak, PEEK SutureTak and PushLock suture anchors infringe a U.S. patent owned by Dr. John O. Hayhurst and under exclusive license to Smith & Nephew Endoscopy -- will be heard this month in Oregon.
A brief history of the case:
- The asserted patent (U.S. Patent Number 5,601,557) covers the use of Smith & Nephew’s TAG WEDGE, TAG ROD, and BIORAPTOR Suture Anchors used primarily in surgical repair of the shoulder.
- In June, 2008, a jury in U.S. District Court in Oregon decided that Arthrex willfully infringed the asserted patent. The jury awarded Smith & Nephew $14.7 million for past infringement.
- In the spring 2009, The United States Patent & Trademark Office (USPTO) overruled Arthrex’s validity challenges to the claims of this patent.
- In November, 2009, The Court of Appeals for the Federal Circuit revised the interpretation of a term in the patent and sent the case back to the Oregon court for a new trial based on that revised claim interpretation.
Smith & Nephew is seeking substantially more damages than originally awarded at the new trial which begins on June 13. Additional products from Arthrex’s SutureTak and PushLock families of suture anchors were added to this dispute, as well as another lawsuit also pending in Oregon.
“We will continue to protect our original products and intellectual property from companies we believe are infringing our patents and profiting from our innovation,” commented Mike Frazzette, president, Smith & Nephew Endoscopy.
Texas patent infringement case against Arthrex
Smith & Nephew Endoscopy sued Arthrex nearly four years ago, claiming that Arthrex’s Retrobutton Femoral Fixation device infringed a U.S. patent owned by Smith & Nephew Endoscopy. The patent asserted in the claim covers Smith & Nephew’s ENDOBUTTON Fixation Device and similar devices for attaching tissue grafts to bone during arthroscopic surgery in the knee.
The United States District Court for the Eastern District of Texas ruled in Smith & Nephew’s favor and found privately-held Arthrex Inc., liable for infringing U.S. Patent 5,645,588. The jury awarded Smith & Nephew $4.7 million for Arthrex’s past infringement.
Arthrex appealed the decision in the Texas case. That appeal was heard by The United States Court of Appeals for the Federal Circuit in April 2011. A decision is expected soon.
Trademark of Smith & Nephew
Contact: Joe Metzger
SVP, Corporate Communications
Smith & Nephew Endoscopy
(978) 749-1330
joe.metzger@smith-nephew.com
About Smith & Nephew
Smith & Nephew is a global medical technology business with global leadership positions in Orthopaedics, including Reconstruction, Trauma and Clinical Therapies; Endoscopy, including Sports Medicine; and Advanced Wound Management. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.
Smith & Nephew is dedicated to helping improve people’s lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company has distribution channels, purchasing agents and buying entities in over 90 countries worldwide. Annual sales in 2010 were nearly $4.0 billion.
Forward-Looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions and our success in integrating acquired businesses; and numerous other matters that affect us or our markets, including those of a political, economic, business or competitive nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith
& Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors.
Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.
SOURCE Smith & Nephew, Inc.
